ArticleClinical cancer research : an official journal of the American Association for Cancer Research2023

Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial.

David S Hong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.